Google Ventures was among the broad range of backers in the genome editing company's series B round, bringing its total funding to more than $160m.

US-based genome editing technology developer Editas Medicine secured $120m today in a series B round backed by Google Ventures, internet company Google’s corporate venturing unit.

Boris Nikolic, managing director of Editas-focused investment firm Bng0, led the round, which included new investors Deerfield Management, Viking Global Investors, Fidelity Management & Research Company, T. Rowe Price, Jennison Associates, Khosla Ventures, EcoR1 Capital, Casdin Capital, Omega Funds, Cowen Private Investments and Alexandria Venture Investments.

Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners…